Evidence map›Paper›PMID 33460532›Full record

ArticlePsychiatry investigation2021

Clozapine Is Better Tolerated in Younger Patients: Risk Factors for Discontinuation from a Nationwide Database in Japan.

Katsunori Toyoda, Takeo Hata, Shigeru Yamauchi, Shinya Kinoshita, Masami Nishihara, Kazuhisa Uchiyama, Ken Inada, Tetsufumi Kanazawa

Open access · diamondAbstract read
In one paragraph

Article in Psychiatry investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Katsunori ToyodaDepartment of Neuropsychiatry, Osaka Medical College, Osaka, Japan.
Takeo HataDepartment of Pharmacy, Osaka Medical College Hospital, Osaka, Japan.
Shigeru YamauchiDepartment of Neuropsychiatry, Osaka Medical College, Osaka, Japan.
Shinya KinoshitaDepartment of Neuropsychiatry, Osaka Medical College, Osaka, Japan.
Masami NishiharaDepartment of Pharmacy, Osaka Medical College Hospital, Osaka, Japan.
Kazuhisa UchiyamaDepartment of Pharmacy, Osaka Medical College Hospital, Osaka, Japan.
Ken InadaDepartment of Psychiatry, Tokyo Women's Medical University, Tokyo, Japan.
Tetsufumi KanazawaDepartment of Neuropsychiatry, Osaka Medical College, Osaka, Japan.
Osaka Medical and Pharmaceutical University · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe effectiveness of clozapine is clearly superior to other antipsychotics in the treatment of refractory schizophrenia. Clozapine leads to various side effects, and therefore many patients are forced to discontinue. In this study, we analyzed the registry database of all cases in Japan to identify risk factors for discontinuation of clozapine.

methodsThe Clozaril patient monitoring service® (CPMS) database from July 31, 2009 to January 26, 2020 was acquired. We defined the following exclusion criteria: patients who had ever taken clozapine by a non-CPMS method, such as an individual import or clinical trial, patients who did not receive clozapine after being enrolled in CPMS, and patients with initial doses other than 12.5 mg (outside the current protocol). Therefore, all patients in this study are new users. Multivariate Cox regression analysis was used to investigate independent risk factors associated with time to discontinuation of clozapine.

resultsWe identified 8,263 patients as the study population. Clozapine discontinuation was significantly associated with age 40 and older [hazard ratio (HR)=1.66, p<0.001], intolerance to olanzapine (HR=1.31, p=0.018), previous treatment with clozapine (HR=1.30, p=0.001), and leukocyte counts <6,000/mm3 (HR=1.24, p<0.001). The Kaplan-Meier curves for clozapine discontinuation by age group revealed that older age at the time of clozapine introduction tended to have lower continuation rates.

conclusionCareful administration is important because patients with these factors have a high risk of discontinuation. In addition, the initiation of clozapine during the younger period was more effective and more tolerated.

Indexed as

AntipsychoticsClozapineContinuation rateLeukopeniaOlanzapineTreatment-resistant schizophrenia

Identifiers

PMID33460532
PMCPMC7960752
OpenAlexW3123783763

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.